These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 31168803)

  • 1. Evaluating the Psychometric Properties of the Migraine Functional Impact Questionnaire (MFIQ).
    Kawata AK; Hareendran A; Shaffer S; Mannix S; Thach A; Desai P; Mikol DD; Ortmeier B; Bayliss M; Buse DC
    Headache; 2019 Sep; 59(8):1253-1269. PubMed ID: 31168803
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Psychometric Evaluation of a Novel Instrument Assessing the Impact of Migraine on Physical Functioning: The Migraine Physical Function Impact Diary.
    Kawata AK; Hsieh R; Bender R; Shaffer S; Revicki DA; Bayliss M; Buse DC; Desai P; Sapra S; Ortmeier B; Hareendran A
    Headache; 2017 Oct; 57(9):1385-1398. PubMed ID: 28857154
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development of a New Tool for Evaluating the Benefit of Preventive Treatments for Migraine on Functional Outcomes - The Migraine Functional Impact Questionnaire (MFIQ).
    Hareendran A; Skalicky A; Mannix S; Lavoie S; Desai P; Bayliss M; Thach AV; Mikol DD; Buse DC
    Headache; 2018 Nov; 58(10):1612-1628. PubMed ID: 30374958
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reducing the physical, social, and emotional impact of episodic migraine: Results from erenumab STRIVE and ARISE phase III randomized trials.
    Kawata AK; Ladd MK; Lipton RB; Buse DC; Bensink M; Shah S; Hareendran A; Mannix S; Mikol D
    Headache; 2022 Feb; 62(2):159-168. PubMed ID: 35137394
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Functional impairment of chronic migraine with medication overuse: Secondary analysis from the Medication Overuse Treatment Strategy (MOTS) trial.
    Shao SC; Hentz J; Shank P; Leonard M; Dodick DW; Schwedt TJ
    Headache; 2024 Jun; 64(6):632-642. PubMed ID: 38780360
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development and validation of a novel patient-reported outcome measure in people with episodic migraine and chronic migraine: The Activity Impairment in Migraine Diary.
    Lipton RB; Gandhi P; Stokes J; Cala ML; Evans CJ; Knoble N; Gelhorn HL; Revicki D; Viswanathan HN; Dodick DW
    Headache; 2022 Jan; 62(1):89-105. PubMed ID: 34962305
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Psychometric validation and meaningful within-patient change of the Migraine-Specific Quality of Life questionnaire version 2.1 electronic patient-reported outcome in patients with episodic and chronic migraine.
    Speck RM; Yu R; Ford JH; Ayer DW; Bhandari R; Wyrwich KW
    Headache; 2021 Mar; 61(3):511-526. PubMed ID: 33481276
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identifying patients who require a change in their current acute migraine treatment: the Migraine Assessment of Current Therapy (Migraine-ACT) questionnaire.
    Dowson AJ; Tepper SJ; Baos V; Baudet F; D'Amico D; Kilminster S
    Curr Med Res Opin; 2004 Jul; 20(7):1125-35. PubMed ID: 15265257
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Validity and reliability of the Greek Migraine-Specific Quality of Life Questionnaire (MSQ Version 2.1-GR).
    Giannouli E; Giannouli E; Alexoudi A; Arvaniti C; Fakas N; Constantinidis TS; Kouremenos E; Mitsikostas DD;
    J Patient Rep Outcomes; 2024 Jul; 8(1):72. PubMed ID: 39007966
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Validating Migraine-Specific Quality of Life Questionnaire v2.1 in episodic and chronic migraine.
    Bagley CL; Rendas-Baum R; Maglinte GA; Yang M; Varon SF; Lee J; Kosinski M
    Headache; 2012 Mar; 52(3):409-21. PubMed ID: 21929662
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Psychometric Evaluation of the Hypogonadism Impact of Symptoms Questionnaire Short Form (HIS-Q-SF).
    Gelhorn HL; Roberts LJ; Khandelwal N; Revicki DA; DeRogatis LR; Dobs A; Hepp Z; Miller MG
    J Sex Med; 2017 Aug; 14(8):1046-1058. PubMed ID: 28760247
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Psychometric Validation of the Role Function Restrictive Domain of the Migraine Specific Quality-of-Life Questionnaire Version 2.1 Electronic Patient-Reported Outcome in Patients With Episodic and Chronic Migraine.
    Speck RM; Shalhoub H; Wyrwich KW; Yu R; Ayer DW; Ford J; Bush EN; Lipton RB
    Headache; 2019 May; 59(5):756-774. PubMed ID: 30861580
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The psychometric properties of the Migraine-Specific Quality of Life Questionnaire version 2.1 (MSQ) in chronic migraine patients.
    Rendas-Baum R; Bloudek LM; Maglinte GA; Varon SF
    Qual Life Res; 2013 Jun; 22(5):1123-33. PubMed ID: 22797868
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Psychometric Validation of the Pulmonary Arterial Hypertension-Symptoms and Impact (PAH-SYMPACT) Questionnaire: Results of the SYMPHONY Trial.
    Chin KM; Gomberg-Maitland M; Channick RN; Cuttica MJ; Fischer A; Frantz RP; Hunsche E; Kleinman L; McConnell JW; McLaughlin VV; Miller CE; Zamanian RT; Zastrow MS; Badesch DB
    Chest; 2018 Oct; 154(4):848-861. PubMed ID: 29705220
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development and exploration of the content validity of a patient-reported outcome measure to evaluate the impact of migraine- the migraine physical function impact diary (MPFID).
    Hareendran A; Mannix S; Skalicky A; Bayliss M; Blumenfeld A; Buse DC; Desai PR; Ortmeier BG; Sapra S
    Health Qual Life Outcomes; 2017 Nov; 15(1):224. PubMed ID: 29149901
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Migraine Headache Day Response Rates and the Implications to Patient Functioning: An Evaluation of 3 Randomized Phase 3 Clinical Trials of Galcanezumab in Patients With Migraine.
    Ford JH; Kurth T; Starling AJ; Ayer DW; Wietecha LA; Port MD; Rettiganti M; Ruff DD
    Headache; 2020 Nov; 60(10):2304-2319. PubMed ID: 33249580
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reliability, validity, and responsiveness of the Arabic version of HIT-6 questionnaire in patients with migraine indicated for preventive therapy: A multi-center study.
    Hussein M; Hassan A; Nada MAF; Mohammed Z; Abdel Ghaffar NF; Kedah H; Fathy W; Magdy R
    Headache; 2024 May; 64(5):500-508. PubMed ID: 38651363
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Psychometric evaluation of the Symptoms of Infection with Coronavirus-19 (SIC): results from a cross-sectional study and a phase 3 clinical trial.
    Chan EKH; Williams V; Romano C; Fehnel S; Slagle AF; Stoddard J; Sadoff J; Mayorga M; Lewis S; Yarr S; Ma J; Liu Y; Katz EG; McNulty P; van Dromme I; McQuarrie K
    J Patient Rep Outcomes; 2023 May; 7(1):45. PubMed ID: 37195456
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Validation and meaningful within-patient change in work productivity and activity impairment questionnaire (WPAI) for episodic or chronic migraine.
    Ford JH; Ye W; Ayer DW; Mi X; Bhandari S; Buse DC; Lipton RB
    J Patient Rep Outcomes; 2023 Apr; 7(1):34. PubMed ID: 37016181
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.